But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

The group plays down upcoming interim analysis, but still hopes for accelerated approval.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.